ALLMedicine™ Hepatitis D Center

Aug 1st, 2021 - Therapy of chronic hepatitis D still relies on interferon alfa. However, efficacy is limited and better therapies are needed. Disruption of the interactions of HDV with the helper HBV or with the host is providing a new therapeutic paradigm and ne...

Jul 25th, 2021 - The hepatitis D virus (HDV) causes the most severe form of chronic hepatitis, often progressing to cirrhosis within 5-10 years. There is no curative treatment and the mechanisms underlying the accelerated liver disease progression are unknown. Inn...

Jul 23rd, 2021 - Hepatitis D virus (HDV) infection causes a severe chronic viral hepatitis with accelerated development of liver cirrhosis and decompensation, but whether it further increases the risk of hepatocellular carcinoma (HCC) is unclear. We performed a co...

Jun 29th, 2021 - Hepatitis D virus infection (HDV) is considered the most severe form of viral hepatitis. In this study, we aimed to evaluate the prevalence of HDV infection in a tertiary center of a large, multi-ethnic city in the Netherlands. Moreover, we valida...

Jun 29th, 2021 - Spontaneous HDV-RNA fluctuations, assessed by nonstandardised in-house assays, have been reported during the course of chronic hepatitis delta (CHD). To evaluate changes in serum HDV-RNA concentrations in untreated CHD patients and correlate these...

Apr 12th, 2019 - This is a multicenter, open-label study of ARC-520 based treatment regimens administered to patients with HBeAg positive or HBeAg negative immune active chronic Hepatitis B Virus (HBV) infection of various genotypes, or patients with Hepatitis D V...

Sep 25th, 2018 - Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. We propose to tre...

Jan 12th, 2018 - This randomized, single blind study will compare the antiviral effect of Pegasys (pegylated interferon alfa-2a) plus placebo versus Pegasys plus tenofovir in patients with chronic hepatitis D. Patients will be randomized to receive 96 weeks of the...

Jul 31st, 2017 - Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. Up to forty-five ...

Jan 20th, 2017 - Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. Twenty-one subjec...

Nov 13th, 2020 - NEW YORK (Reuters Health) - Several risk factors associated with hepatitis D virus (HDV) infection can be used to identify people who should be screened, researchers report. "It was interesting to find that the risk factors that were identified in...

Dec 20th, 2019 - NEW YORK (Reuters Health) - Hepatitis delta virus (HDV) infection, which occurs only as a co-infection with acute hepatitis B (HBV) or a superinfection with chronic HBV, is associated with higher healthcare utilization and costs than HBV alone, a ...

Nov 8th, 2019 - BOSTON – For most patients with chronic hepatitis D virus (HDV) infection, combination therapy with lonafarnib, ritonavir, and peginterferon may significantly decrease viral loads, based on interim results from the phase IIa LIFT trial. After 6 mo.

Apr 20th, 2018 - What is the hepatitis virus? Well, the hepatitis virus invades liver cells and causes inflammation in the liver tissue. Five hepatitis viruses are recognized: hepatitis A, hepatitis B, hepatitis C, hepatitis D, and hepatitis E. They all have sligh...

What is the purpose of the Surrogate Endpoint Table? FDA’s surrogate endpoint table provides valuable information for drug developers on endpoints that may be considered and discussed with FDA for individual development programs. This table also f...